 |
Publisher: Peytchinski Publishing Ltd.
ISSN: 1312-773X (Online)
Issue: 2025, vol. 31, issue1
Subject Area: Medicine
-
DOI: 10.5272/jimab.2025311.5989
Published online: 10 Febrary 2025
Original article
J of IMAB. 2025 Jan-Mar;31(1):5989-5997
EPIDEMIOLOGICAL INVESTIGATION OF THE CLINICAL MANIFESTATION OF BISPHOSPHONATE-ASSOCIATED OSTEONECROSIS OF THE JAWS IN 112 ONCOLOGY PATIENTS
Meri Hristamyan1
, Ralitsa Raycheva2, Veselka Hristamyan3,
1) Department of Epidemiology and Disaster Medicine, Faculty of Public Health, Medical University of Plovdiv, Bulgaria.
2) Department of Social Medicine and Public Health, Faculty of Public Health, Medical University of Plovdiv, Bulgaria.
3) Clinic of Maxillo-facial Surgery, UMHAT St. George - Plovdiv, Bulgaria.
ABSTRACT:
Background: Bisphosphonate-associated osteonecrosis of the jaws (BAONJ) is a condition linked to the intake of Bisphosphonates (BP) and clinically manifesting in mucosal ulceration and exposure of underlying necrotic bone. The aim of the study is to analyze the clinical manifestation, paraclinical methods for diagnosis, and treatment methods of BAONJ in oncology patients.
Methods: A prospective epidemiological study of 112 oncology patients diagnosed with BAONJ was conducted in the Clinic of maxillo-facial surgery of UMHAT "St. George", Plovdiv, Bulgaria. SPSS Statistics v.24 was used for statistical analysis at a significance level of p<0.05.
Results: The main diagnostic methods were clinical examination and history taking, with X-rays in 91.96% (n=103). Half of the patients were diagnosed at stage II, 29.46% at stage I, 17.86% at stage III, and 1.79% at stage 0. The highest proportion of patients (71.41%, n=80) reported pain in the jaws, about 2/3 - exposed bone (65.18%, n=73), and swelling/edema (60.71%, n=68). Treatment included an antibiotic in 54.45% (n=61) of the β-lactam antibiotics group. Debridement was performed in 32.14% (n=36) of cases, followed by other surgical manipulation in 18.75% (n=21) and resection in 4.56% (n=5).
Conclusion: BAONJ is diagnosed late, which leads to the necessity of surgical treatment.
Keywords: bisphosphonates, osteonecrosis, jaw, clinical manifestation, oncology, epidemiology,
- Download FULL TEXT /PDF 1232 KB/
Please cite this article as: Hristamyan M, Raycheva R, Hristamyan V. Epidemiological investigation of the clinical manifestation of Bisphosphonate-associated Osteonecrosis of the jaws in 112 oncology patients. J of IMAB. 2025 Jan-Mar;31(1):5989-5997. [Crossref - 10.5272/jimab.2025311.5989]
Correspondence to: Dr Meri Hristamyan, PhD, Department of Epidemiology and DM, Faculty of Public Health, Medical University - Plovdiv; 15A, Vasil Aprilov Str., Plovdiv, Bulgaria; E-mail: Meri.Hristamyan@mu-plovdiv.bg
REFERENCES:
1. Zhang J, Bai H, Bai M, Wang X, Li Z, Xue H, et al. Bisphosphonate-incorporated coatings for orthopedic implants functionalization. Mater Today Bio. 2023 Jul 22;22:100737. [PubMed]
2. Ruggiero SL, Dodson TB, Aghaloo T, Carlson ER, Ward BB, Kademani D. American Association of Oral and Maxillofacial Surgeons’ Position Paper on Medication-Related Osteonecrosis of the Jaws-2022 Update. J Oral Maxillofac Surg. 2022 May;80(5):920-943. [PubMed]
3. Martins LHI, Ferreira DC, Silva MT, Motta RHL, Franquez RT, Bergamaschi CC. Frequency of osteonecrosis in bisphosphonate users submitted to dental procedures: A systematic review. Oral Dis. 2023 Jan;29(1):75-99. [PubMed]
4. Dunphy L, Salzano G, Gerber B, Graystone J. Medication-related osteonecrosis (MRONJ) of the mandible and maxilla. BMJ Case Rep. 2020 Jan 5;13(1):e224455. [PubMed]
5. Chien HI, Chen LW, Liu WC, Lin CT, Ho YY, Tsai WH, et al. Bisphosphonate-Related Osteonecrosis of the Jaw. Ann Plast Surg. 2021 Feb 1;86(2S Suppl 1):S78-S83. [PubMed]
6. Klingelhöffer C, Zeman F, Meier J, Reichert TE, Ettl T. Evaluation of surgical outcome and influencing risk factors in patients with medication-related osteonecrosis of the jaws. J Craniomaxillofac Surg. 2016 Oct;44(10):1694-1699. [PubMed]
7. Wang Q, Liu J, Qi S, Liao X, Liu D, Pan J. Clinical analysis of medication related osteonecrosis of the jaws: A growing severe complication in China. J Dent Sci. 2018 Sep;13(3):190-197. [PubMed]
8. Aksoy MЗ, Kocer G, Kocer M, Baykul T. Medication related osteonecrosis of the jaws. A case serial study. Int J Clin Exp Med. 2017 Nov;10(11):15672-15679. [Internet]
9. Matsuda S, Yoshimura H, Sano K. Risk factors and treatments for medication-related osteonecrosis of the jaw: A 10-year single-institution experience. Journal of Oral and Maxillofacial Surgery, Medicine, and Pathology. J Oral Maxillofac Surg Med Pathol. 2018 Jan;30(1):10-16. [Crossref]
10. O'Ryan FS, Khoury S, Liao W, Han MM, Hui RL, Baer D, et al. Intravenous Bisphosphonate-Related Osteonecrosis of the Jaw: Bone Scintigraphy as an Early Indicato. J Oral Maxillofac Surg. 2009 Jul;67(7):1363-72. [PubMed]
11. Thumbigere-Math V, Sabino MC, Gopalakrishnan R, Huckabay S, Dudek AZ, Basu S, et al. Bisphosphonate-related osteonecrosis of the jaw: clinical features, risk factors, management, and treatment outcomes of 26 patients. J Oral Maxillofac Surg. 2009 Sep; 67(9):1904-13. [PubMed]
12. Panya S, Fliefel R, Probst F, Tröltzsch M, Ehrenfeld M, Schubert S, et al. Role of microbiological culture and polymerase chain reaction (PCR) of actinomyces in medication-related osteonecrosis of the jaw (MRONJ). J Craniomaxillofac Surg. 2017 Mar; 45(3):357-363. [PubMed]
13. Pelaz A, Junquera L, Gallego L, García-Consuegra L, García-Martínez L, Cutilli T, et al. Epidemiology, pharmacology and clinical characterization of bisphosphonate-related osteonecrosis of the jaw. A retrospective study of 70 cases. Acta Otorrinolaringol Esp. 2015 May-Jun; 66(3):139-47. [PubMed]
14. Stockmann P, Hinkmann FM, Lell MM, Fenner M, Vairaktaris E, Neukam FW, et al. Panoramic radiograph, computed tomography or magnetic resonance imaging. Which imaging technique should be preferred in bisphosphonate-associated osteonecrosis of the jaw? A prospective clinical study. Clin Oral Investig. 2010 Jun; 14(3):311-7. [PubMed]
15. Guo Y, Wang D, Wang Y, Peng X, Guo C. Imaging features of medicine-related osteonecrosis of the jaws: comparison between panoramic radiography and computed tomography. Oral Surg Oral Med Oral Pathol Oral Radiol. 2016 Aug; 122(2):e69-76. [PubMed]
16. Baba A, Goto TK, Ojiri H, Takagiwa M, Hiraga C, Okamura M, et al. CT imaging features of antiresorptive agent-related osteonecrosis of the jaw/medication-related osteonecrosis of the jaw. Dentomaxillofac Radiol. 2018 May;47(4):20170323. [PubMed]
17. Demir A, Pekiner FN. Radiographic findings of bisphosphonate-related osteonecrosis of the jaws: Comparison with cone-beam computed tomography and panoramic radiography. Niger J Clin Pract. 2017 Mar;20(3):346-354. [PubMed]
18. Biasotto M, Chiandussi S, Dore F, Rinaldi A, Rizzardi C, Cavalli F, et al. Clinical aspects and management of bisphosphonates-associated osteonecrosis of the jaws. Acta Odontol Scand. 2006 Nov;64(6):348-54. [PubMed]
19. Watanabe S, Nakajima K, Kinuya S. &Symposium: Imaging modalities for drug-related osteonecrosis of the jaw (5), utility of bone scintigraphy and 18F-FDG PET/CT in early detection and risk assessment of medication-related osteonecrosis of the jaw (secondary publication). Jpn Dent Sci Rev. 2019 Nov;55(1):76-79. [PubMed]
20. Moridera K, Kitajima K, Yoshikawa K, Takaoka K, Tsuchitani T, Noguchi K, et al. Usefulness of quantitative bone SPECT/CT for medication-related osteonecrosis of the jaw in clinical settings. Jpn J Radiol. 2022 May;40(5):492-499. [PubMed]
21. Otto S, Schreyer C, Hafner S, Mast G, Ehrenfeld M, Stürzenbaum S, et al. Bisphosphonate-Related Osteonecrosis of the Jaws-Characteristics, Risk Factor, Clinical Features, Localization and Impact on Oncological Treatment. J Craniomaxillofac Surg. 2012 Jun;40(4):303-9. [PubMed]
22. Schipmann S, Metzler P, Rössle M, Zemann W, von Jackowski J, Obwegeser JA, et al. Osteopathology associated with bone resorption inhibitors - which role does Actinomyces play? A presentation of 51 cases with systematic review of the literature. J Oral Pathol Med. 2013 Sep;42(8):587-93. [PubMed]
23. Abel Mahedi Mohamed H, Nielsen CEN, Schiodt M. Medication related osteonecrosis of the jaws associated with targeted therapy as monotherapy and in combination with antiresorptives. A report of 7 cases from the Copenhagen Cohort. Oral Surg Oral Med Oral Pathol Oral Radiol. 2018 Feb;125(2):157-163. [PubMed]
24. Guo YX, Wang DC, Wang Y, Peng X, Mao C, Guo CB. [Clinical features of osteonecrosis of jaws after bisphosphonates therapy for bone metastasis of breast cancer]. [in Chinese] Beijing Da Xue Xue Bao Yi Xue Ban. 2016 Feb 18;48(1):80-3. [PubMed]
25. Vescovi P, Merigo E, Meleti M, Manfredi M, Guidotti R, Nammour S. Bisphosphonatesrelated osteonecrosis of the jaws: a concise review of the literature and a report of a singlecentre experience with 151 patients. J Oral Pathol Med. 2012 Mar;41(3):214-21. [PubMed]
26. de Boissieu P, Gaboriau L, Morel A, Trenque T. Bisphosphonate-related osteonecrosis of the jaw: data from the French national pharmacovigilance database. Fundam Clin Pharmacol. 2016 Oct;30(5):450-8. [PubMed]
27. Alsehimy ММ. Efficacy of a non-surgical treatment regimen in patients with bisphosphonate-related osteonecrosis of the jaws in Saudi Arabia. SAGE Open Medicine. 2017 Feb 14;2:2050312114522995. [PubMed]
28. Thumbigere-Math V, Michalowicz BS, Hodges JS, Tsai ML, Swenson KK, Rockwell L, et al. Periodontal disease as a risk factor for bisphosphonate-related osteonecrosis of the jaw. J Periodontol. 2014 Feb;85(2):226-33. [PubMed]
29. Dal Prá KJ, Lemos CA, Okamoto R, Soubhia AM, Pellizzer EP. Efficacy of the C-terminal telopeptide test in predicting the development of bisphosphonate-related osteonecrosis of the jaw: a systematic review. Int J Oral Maxillofac Surg. 2017 Feb;46(2):151-156. [PubMed]
30. Soutome S, Otsuru M, Hayashida S, Murata M, Yanamoto S, Sawada S, et al. Relationship between tooth extraction and development of medication-related osteonecrosis of the jaw in cancer patients. Sci Rep. 2021 Aug 26;11(1):17226. [PubMed]
31. Koth VS, Figueiredo MA, Salum FG, Cherubini K. Interrelationship of clinical,radiographic and haematological features in patients under bisphosphonate therapy. Dentomaxillofac Radiol. 2017 Apr;46(4):20160260. [PubMed]
32. de Almeida AD, Leite FG, Chaud MV, Rebelo MA, Borges LCFS, Viroel FJM, et al. Safety and efficacy of hydroxyapatite scaffold in the prevention of jaw osteonecrosis in vivo. J Biomed Mater Res B Appl Biomater. 2018 Jul;106(5):1799-1808. [PubMed]
33. Hinson AM, Smith CW, Siegel ER, Stack BC Jr. Is bisphosphonate-related osteonecrosis of the jaw an infection? A histological and microbiological ten-year summary. Int J Dent. 2014;2014:452737. [PubMed]
34. Badros A, Weikel D, Salama A, Goloubeva O, Schneider A, Rapoport A, et al. Osteonecrosis of the jaw in multiple myeloma patients: clinical features and risk factors. J Clin Oncol. 2006 Feb 20;24(6):945-52. [PubMed]
35. Janovska Z, Mottl R, Slezak R. Experience with the treatment of bisphosphonate-related osteonecrosis of the jaw. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2015 Jun;159(2):313-7. [PubMed]
36. Zadik Y. Clarithromycin as the empiric antibiotic therapy for medication-related osteonecrosis of the jaw in multiple myeloma patients. Oral Oncol. 2018 Sep;84:104-105. [PubMed]
37. De Bruyn L, Coropciuc R, Coucke W, Politis C. Microbial population changes in patients with medication-related osteonecrosis of the jaw treated with systemic antibiotics. Oral Surg Oral Med Oral Pathol Oral Radiol. 2018 Mar;125(3):268-275. [PubMed]
38. Amin H, Andersen SWM, Jensen SS, Kofod T. Surgical and conservative treatment outcomes of medication-related osteonecrosis of the jaw located at tori: a retrospective study. Oral Maxillofac Surg. 2024 Sep;28(3):1117-1125. [PubMed]
39. Kaibuchi N, Hoshi K, Yamazaki A, Miyamoto-Sangu N, Akagi Y, Okamoto T. The progress of medication-related osteonecrosis of the jaw with conservative initial treatment: A 12-year retrospective study of 129 patients. Bone Rep. 2021 Apr 21;14:101072. [PubMed]
40. Coropciuc RG, Grisar K, Aerden T, Schol M, Schoenaers J, Politis C. Medication-relatedosteonecrosis of the jaw in oncological patients with skeletal metastases: conservative treatment is effective up to stage 2. Br J Oral Maxillofac Surg. 2017 Oct;55(8):787-792. [PubMed]
Received: 18 July 2024
Published online: 10 February 2025